Interim Chief Executive Officer
Immodulon Therapeutics Ltd
United States of America
Dr Kevin Bilyard is an experienced industry executive who served as CEO of Immodulon from 2008 to 2016 and has more recently been an advisor to the company’s Board of Directors. His career includes senior roles in product development and product strategy at GSK, AstraZeneca and Quadrant Healthcare, prior to its acquisition by Elan. He is the co-founder of a successful international healthcare consultancy business, through which he has worked with many growth stage pharmaceutical companies in Europe and the USA.
Biopharmaceutical company, immunotherapy treatments, cancer